SCHEMBL14859138

SCHEMBL14859138

Cc1cccc(CNC(=O)N(S)C(=O)c2ccc(C(C)(C)C)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 7/20 0.52
▸ RAB9A P51151 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ EPHX2 P34913 7/20 0.48
▸ KCNK3 O14649 1/20 0.44
▸ MAPT P10636 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ MMP13 P45452 1/20 0.43
▸ HDAC3 O15379 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14859828 0.89 MMP13 (0.47) NR1H4RAB9ALMNAMAPTNPC1
SCHEMBL14859888 0.87 NR1H4 (0.51) NR1H4RAB9ALMNAEPHX2MAPT
SCHEMBL14860316 0.85 EPHX2 (0.59) NR1H4RAB9ALMNAEPHX2MAPT
SCHEMBL14859532 0.83 NR1H4 (0.50) NR1H4RAB9ALMNAEPHX2NPC1
SCHEMBL14860301 0.80 MEN1 (0.67) NR1H4RAB9ALMNAEPHX2NPC1
SCHEMBL14860245 0.80 EPHX2 (0.54) NR1H4RAB9ALMNAEPHX2MAPT
SCHEMBL14860198 0.80 KCNK3 (0.60) NR1H4RAB9ALMNAKCNK3MAPT
SCHEMBL14860135 0.79 HPGD (0.50) NR1H4RAB9ALMNAEPHX2MAPT
SCHEMBL14859225 0.77 RAB9A (0.67) NR1H4RAB9ALMNAEPHX2MAPT
SCHEMBL12069911 0.76 ALDH1A1 (0.66) NR1H4RAB9ALMNAEPHX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP claimed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US claimed
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP disclosed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT UGP2, TPMT, UPP1 NR1H4 4314/4885RAB9A 2456/4885LMNA 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback